Going forward..., page-1424

Hi@Rossi70,

There has been an announcement made back in May 2018 regarding the pre-clinical studies, which were conducted by the Cooperative Research Centre for Cell Therapy Manufacturing (CTM CRC - "Discussions between Cynata and CTM CRC are underway regarding progressing Cymerus MSCs and CTM CRC’s wound-dressing technology into a clinical trial in human patients with diabetic foot ulcers"):
http://files.cynata.com/348/18.05.31.Cynatas-MSCs-Effective-in-Model-of-Diabetic-Wounds.pdf

Since then, the CRC funding has been terminated (see exit report March 2019):
https://www.ctmcrc.com/wp-content/uploads/2019/03/2019CTMCRC-ExitReport_FINAL-lowres2.pdf

"Finally, the management company, CTM@CRC Ltd will continue to operate as a registered charity after termination of CRC funding. As a significant shareholder in both Carina and TekCyte, CTM@CRC will have the ongoing opportunity to support related research if the companies achieve significant capital growth. Essentially CTM@CRC will continue the purpose of the CRC.

In conclusion, I would like to thank and congratulate the Board, Audit and Risk Committee, Management, Researchers and Participants for a very successful CRC. It has been a privilege to chair CTM CRC as well as take on the additional role of CEO over the last year.

If we can achieve the planned legacies of two highgrowth spin-out companies, plus a well-funded charity in CTM, we will have done the CRC program proud!"
Dr Leanna Read, CEO CTM CRC

The same exit statement also mentions:
"A coating that enables wound dressings to act as carriers for therapeutic cells, significantly improving wound closure. A clinical trial is planned with a UK partner using stem cells from an Australian SME."
(page 8)

"TekCyte, which is commercialising the dressing, has determined that only a small number of cells are required which means the product can be produced at a low cost and positioned very competitively against existing advanced wound care products."
(page 14)

"TekCyte
CTM CRC’s second spin-out company, TekCyte Pty Ltd, has been established to develop commercial applications arising from CTM CRC’s core capabilities in coating surfaces to enhance their biological function. The markets include cultureware for use in research laboratories or for therapeutic cell expansion, as well as coatings for medical devices including vascular stents and wound dressings.

[...]

Started dealing with an Australian cell therapy company – Cynata Ltd, to commercialise its coated wound dressing. Preclinical results have provided strong evidence of the potential for the treatment to improve the healing of chronic wounds in diabetic patients, which costs the
Australian healthcare system more than $3b annually. TekCyte is now working with Cynata and organisations in the UK to initiate a first-in-man clinical trial."
(page 20)

You can find a short video about TekCyte in my previous post (since it seems to delete the whole text if I post a/the Tweet in here).


You are wondering why nothing has been announced by Cynata via the ASX?
Technically there is nothing new here compared to the original ASX announcement, except that CTM CRC's spin-out company TekCyte is now in charge. But the pre-clinical results and the ultimate goal of commencing a clinical trial has not (doesn't seem to have) changed.


Since posting about the $45 million investor injection yesterday, I have contacted the Media Office of The University of Adelaide (details can be found in yesterday's post) as I was a bit confused by the image and certain statements.

Dr Leanne Read, former CEO of CTM CRC and now TekCyte Chair, is shaking hands with Mr An, Executive Director of D&R Pharmaceuticals, who holds a red folder in his hand with "MOU" written on it.

(source: TekCyte Tweet, see yesterday's post)

I was told that in fact TekCyte has signed an MOU with D&R Pharmaceuticals as part of the launch ceremony of The Adelaide China Biotech Investment Fund. I was told that this MOU was the first one signed.


Lets hope that this red folder contains pages with the words "wound care" written on them